PuriActives® NanoActive Nano-Encapsulation Platform ·
PURIPHARM CO., LTD.
NanoActive ELA — Nano-Encapsulated Ellagic Acid
Unlocking the multi-dimensional skincare and haircare potential
of ellagic acid through nano-delivery
INCI NAME: ELLAGIC ACID ｜ CAS 476-66-4
01 · WHY ELLAGIC ACID · THE MOLECULE
A natural polyphenol active, validated again and again
From a single molecule, ellagic acid spans five skin-biology themes: skin tone management, oxidative stress, photoaging, inflammatory modulation, and the follicular microenvironment. Since its first cosmetic-science publication in 2000, skin- and hair-related evidence for ellagic acid has accumulated across four levels: in-vitro enzymology, cell models, animal models, and human randomized controlled trials.
Skin tone management
Reversible tyrosinase inhibition and MITF signaling down-regulation; a randomized double-blind human trial showed that 4 weeks of an ellagic acid-rich extract inhibits UV-induced pigmentation.
Oxidative stress defense
Direct radical scavenging plus up-regulation of the endogenous Nrf2 / HO-1 / SOD antioxidant system, protecting keratinocytes and fibroblasts from UV oxidative damage.
Photoaging protection
In UVB animal models, reduces wrinkle formation and epidermal thickening, inhibits MMP secretion and collagen degradation, and down-regulates inflammatory signals such as IL-1β and IL-6.
Scalp & follicular microenvironment
Inhibits DHT-induced ferroptosis in dermal papilla cells and activates Wnt/β-catenin signaling.
Sources — Kasai et al., J Nutr Sci Vitaminol 2006 · Hseu et al., Food Chem Toxicol 2012 · Bae et al., Exp Dermatol 2010 · Fu et al., J Ethnopharmacol 2024
02 · MOLECULAR PROFILE · THE SCIENCE
Ellagic acid: a highly conjugated polyphenolic dilactone
| Common name | Ellagic acid |
| INCI | ELLAGIC ACID |
| CAS No. | 476-66-4 |
| Formula / MW | C₁₄H₆O₈ / 302.19 g·mol⁻¹ |
| Chemical class | Hydrolysable-tannin-derived polyphenolic dilactone |
| IUPAC | 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione |
| Natural sources | Pomegranate, berries, nuts, Chinese gallnut, etc. |
Structure–activity relationship
● 4 phenolic hydroxyls: donate hydrogen to quench free radicals — the basis of antioxidant activity
● Vicinal phenolic hydroxyls: chelate metal ions such as Cu²⁺, acting on the tyrosinase active center
● Highly conjugated rigid scaffold + two lactone rings: both electron-donor and acceptor sites, strong redox activity
Sources — Ríos et al., Planta Med 2018;84:1068–1093 · Castellacci & Bergonzi, Molecules 2025;30:4493 · Mantzourani et al., Separations 2024;11:174
03 · MULTI-DIMENSIONAL SKIN BIOLOGY · THE SCIENCE
One molecule, five dimensions
Each of the five dimensions is supported by research in skin, scalp, or their cell models — the following chapters walk through them one by one.
04 · SKIN TONE MANAGEMENT (I) · SKIN TONE
Targeting tyrosinase: melanin control from the active center up
Tyrosinase inhibition IC₅₀ = 0.2 ± 0.05 mM
In-vitro mushroom tyrosinase kinetics: ellagic acid is a reversible, mixed-type inhibitor whose binding relies on hydrogen bonds and electrostatic interactions (Huang et al., 2019)
Consistent evidence from enzymology to cells and animal models
● A defined site of action: ellagic acid chelates the Cu²⁺ at the tyrosinase active center — reversible inhibition that does not damage melanocytes (Shimogaki et al., 2000)
● Cellular level: melanogenesis suppressed in B16 melanoma cells; removing ellagic acid restores melanin synthesis, indicating a non-cytotoxic mechanism (Shimogaki et al., 2000)
● Animal level: inhibits UV-induced skin pigmentation in the brown guinea pig model (Shimogaki et al., 2000; Yoshimura et al., 2005)
● Kinetic support: ellagic acid can enter the melanin biosynthesis pathway directly and be oxidized by tyrosinase, interfering with the melanization process (Ortiz-Ruiz et al., 2016)
Sources — Huang et al., J Food Biochem 2019;43:e12996 · Shimogaki et al., Int J Cosmet Sci 2000;22:291–303 · Yoshimura et al., Biosci Biotechnol Biochem 2005;69:2368–2373 · Ortiz-Ruiz et al., J Dermatol Sci 2016;82:115–122
05 · SKIN TONE MANAGEMENT (II) · SKIN TONE
A complete chain from signaling pathways to human evidence
Human-level skin tone evidence
2006 Randomized double-blind placebo-controlled trial — oral ellagic acid-rich (90%) pomegranate extract at 100 / 200 mg·d⁻¹ × 4 weeks inhibited UV-induced skin pigmentation (Kasai et al.)
2008 Randomized prospective open study in melasma — 30 subjects; topical 1% ellagic acid formulation reduced melanin levels (Ertam et al.)
2013 Comparative evaluation vs. 4% hydroquinone — a formula of 0.5% ellagic acid + 0.1% salicylic acid was comparable to 4% hydroquinone in reducing the appearance of dark spots, with good tolerability (Dahl et al.)
Mechanism verification: the autophagy inhibitor 3-MA or LC3 silencing markedly weakens ellagic acid’s anti-melanogenic effect; an in-vivo zebrafish model confirms inhibition of tyrosinase activity and endogenous pigmentation (Yang et al., 2021).
Cosmetic-language translation: improving dull skin tone · evening skin tone · enhancing skin radiance · reducing the appearance of dark spots · improving photodamage-related uneven tone
Sources — Yang et al., Biochem Pharmacol 2021;185:114454 · Kasai et al., J Nutr Sci Vitaminol 2006;52:383–388 · Ertam et al., J Dermatol 2008;35:570–574 · Dahl et al., J Drugs Dermatol 2013;12:52–58
06 · OXIDATIVE STRESS DEFENSE · ANTIOXIDANT
From radical scavenging to activating the endogenous antioxidant system
DPPH radical scavenging IC₅₀ = 4.86 µM
Measured by in-vitro chemiluminescence assay (Muddathir et al., 2013)
Keratinocytes: UVA oxidative stress model
HaCaT cells pretreated with ellagic acid before UVA irradiation: intracellular ROS and the lipid-peroxidation product MDA decreased, mitochondrial function and DNA integrity were protected, and Nrf2 / HO-1 / SOD expression was up-regulated (Hseu et al., 2012).
Fibroblasts: UVB oxidative stress model
In a human dermal fibroblast UVB model, ellagic acid lowered intracellular ROS and MMP-2 and restored UVB-suppressed Nrf2 levels, indicating up-regulation of the antioxidant response element pathway (Baek et al., 2016).
Ellagic acid’s antioxidant action is not single-point scavenging: beyond direct radical quenching by phenolic hydroxyls, it up-regulates the endogenous antioxidant enzyme system via the Nrf2 / ARE axis — a dual-layer “direct scavenging + systemic defense” mechanism.
Formulation translation: antioxidant serums · urban defense · anti-pollution care · the mechanistic basis for daytime defense products
Sources — Hseu et al., Food Chem Toxicol 2012;50:1245–1255 · Baek et al., Korean J Physiol Pharmacol 2016;20:269–277 · Muddathir et al., J Wood Sci 2013;59:426–431 · Yang et al., Biochem Pharmacol 2021;185:114454
07 · PHOTOAGING PROTECTION · PHOTOAGING
Breaking the UV → ROS → MAPK / AP-1 → MMP damage cascade
UVB hairless mouse model (Bae et al., 2010)
● Ellagic acid treatment reduced UVB-induced wrinkle formation and epidermal thickening
● Inhibited MMP secretion and collagen degradation, and down-regulated inflammatory factors including IL-1β and IL-6
● Indicates ellagic acid acts simultaneously on the three photoaging links: oxidation — inflammation — matrix degradation
Positive support for matrix synthesis: in human dermal fibroblasts, ellagic acid — alone or combined with retinoic acid — promotes collagen and elastin production (Duckworth et al., 2023).
Sources — Bae et al., Exp Dermatol 2010;19:e182–e190 · Abd-Elghany & Mohamad, ACS Omega 2023;8:16620–16629 · Duckworth et al., Biomed Mater Eng 2023;34:473–480
08 · SOOTHING & SKIN HOMEOSTASIS · SOOTHING
Bidirectional regulation of oxidation and inflammation
Post-UVB inflammatory gene profile in keratinocytes
After UVB irradiation of HaCaT cells, ellagic acid significantly down-regulated the inflammatory gene expression of IL-1β, IL-6, IL-8, IL-10, MCP-1 and TNF-α (Lembo et al., 2014).
MAPK / STAT pathways and barrier homeostasis
In TNF-α / IFN-γ-stimulated keratinocytes, ellagic acid inhibited pro-inflammatory cytokine production via MAPK and STAT pathways; in an atopic-dermatitis-like mouse model it improved skin condition and lowered TEWL as well as serum IgE, IL-6 and TNF-α levels (Gil et al., 2021).
Oxidative stress and inflammatory signaling amplify each other: ROS activates NF-κB / MAPK, and inflammation further amplifies ROS. Ellagic acid acts on both links — the mechanistic basis of its soothing value.
Cosmetic-language translation: soothing · improvement of red/sensitive states · post-sun skin comfort · environmental stress defense · skin homeostasis support
Sources — Lembo et al., Biomed Res Int 2014;2014:346793 · Gil et al., Int J Mol Sci 2021;22:1277 · Bae et al., Exp Dermatol 2010;19:e182–e190 · Han et al., Adv Tradit Med 2024;25:723–733
09 · SCALP & FOLLICLE HEALTH · HAIR & SCALP
Extending skin science into the follicular microenvironment
Direct follicle research evidence
Fu et al. (2024, J Ethnopharmacol): ellagic acid inhibits DHT-induced ferroptosis in dermal papilla cells, restores mitochondrial function, activates Wnt/β-catenin signaling, and supports hair regrowth in a mouse model.
Dermal papilla cell proliferation evidence (in vitro)
Park et al. (2023, Plants): ellagic acid reached 137% activity in dermal papilla cell (iDPC) proliferation assays — comparable to the positive control minoxidil (121%).
Scalp mechanisms shared with skin
The scalp is an extension of the skin: ROS scavenging, Nrf2 activation and NF-κB down-regulation apply equally to scalp antioxidant and soothing scenarios; chestnut bur extract (with ellagic acid as an active component) blocks C. acnes-induced TLR2 / NF-κB activation (You et al., 2022).
Robust yet defensible wording: supporting a healthy follicular microenvironment · mitigating oxidative-stress impact on follicles · supporting scalp homeostasis · maintaining hair vitality
Sources — Fu et al., J Ethnopharmacol 2024;330:118227 · Park et al., Plants 2023;12:1018 · You et al., Appl Biol Chem 2022;65:12
10 · THE APPLICATION CHALLENGE · THE CHALLENGE
Ellagic acid is powerful — but not easy to use
Formulation & delivery barriers of conventional ellagic acid
● Poor aqueous solubility: only ~9.7 µg/mL in water — hard to build effective concentrations in water-based formulas (Bala et al., 2006)
● Unfavorable oil/water partitioning: logP ≈ 0.52, making it difficult to cross the dense stratum corneum barrier (Yang et al., 2025)
● BCS Class IV molecule: doubly limited by low solubility + low permeability (Nyamba et al., 2021)
● Crystallization & aggregation: the highly rigid conjugated scaffold crystallizes readily, causing insufficient formulation homogeneity, uneven content, and appearance/stability risks
● Limited high loading: dispersion difficulties make high-load formulas hard to achieve, resulting in low practical utilization
High bioactivity ≠ high formulation efficiency — this is exactly the question NanoActive ELA answers
Sources — Bala et al., J Pharm Biomed Anal 2006;40:206–210 · Nyamba et al., Eur J Pharm Biopharm 2021;159:198–210 · Yang et al., Sci Rep 2025;15:27183 · Ceci et al., Nanotechnology 2020;31:382001
11 · NANOACTIVE NANO-DELIVERY · THE SOLUTION
NanoActive ELA: designed for poorly soluble actives
Rebuilding the physical form of ellagic acid with nano-encapsulation: turning a molecule that is scientifically strong but hard to use into a high-value active ingredient adapted to modern cosmetic formulation systems.
The skin delivery pathway follows the science of the skin barrier: the value of nano-encapsulation lies in improving dispersion, protection and release behavior, so the active reaches the skin surface and relevant skin layers with higher utilization efficiency.
12 · TECHNICAL LOGIC · THE SOLUTION
What happens when particle size shrinks?
01 Dispersion
Uniform nanoscale dispersion in the aqueous phase. Literature ellagic acid vesicle systems: 124–752 nm, PDI < 0.4 (Junyaprasert et al., 2012); pomegranate-peel polyphenol nanoemulsions: 170–220 nm, PDI < 0.2, encapsulation efficiency 70–80% (Baccarin & Lemos-Senna, 2017).
02 Protection
Lipid-matrix encapsulation isolates the active from light and oxygen. Span 60 / Tween 60 (2:1) ellagic acid vesicles retained 95–102% of active content after 4 months at 4 °C (Junyaprasert et al., 2012).
03 Delivery
Improved distribution and retention in skin. Ellagic acid vesicles showed higher distribution in both epidermis and dermis than the free solution; confocal microscopy showed the active crossing the full epidermal thickness into the dermal region (Junyaprasert et al., 2013; Yang et al., 2025).
04 Release
Sustained-release behavior extends the active’s working time. Under simulated skin microenvironment conditions (pH 5.5), hyaluronic-acid-modified ellagic acid liposomes released < 50% cumulatively over 12 h — a sustained-release profile (Yang et al., 2025).
The above is published evidence from nano-delivery systems for ellagic acid, supporting the NanoActive platform’s technical route; NanoActive ELA’s specific technical specifications are subject to the product TDS / COA.
13 · VALUE COMPARISON · THE VALUE
From a good molecule to a good ingredient
| Dimension | Conventional ellagic acid | NanoActive ELA |
|---|---|---|
| Dispersibility | Limited | Optimized |
| Aqueous-phase compatibility | Low | Improved |
| Crystal aggregation risk | High | Reduced |
| Formulation homogeneity | Constrained | Enhanced |
| Active protection | Limited | Encapsulation-protected |
| Effective surface area | Low | Significantly increased |
| Topical delivery efficiency | Constrained | Optimized |
| Formulation flexibility | Low | Enhanced |
Oligomeric-hyaluronic-acid-modified ellagic acid liposomes (EA-HA5k-L) achieved 1.65× and 1.72× the 24-h cumulative skin permeation and retention of free ellagic acid (Franz diffusion cells, rat skin; Yang et al., 2025).
Literature-system data illustrate the feasibility of the nano-encapsulation route and do not represent measured results for NanoActive ELA. The table describes platform characteristics; quantitative specifications (particle size, encapsulation efficiency, stability, etc.) are subject to the NanoActive ELA product TDS / COA.
Sources — Yang et al., Sci Rep 2025;15:27183 · Junyaprasert et al., Int J Pharm 2012;423:303–311 · Singh Hallan et al., Molecules 2020;25:1449
14 · SKINCARE APPLICATION MAP · SKINCARE APPLICATION
From mechanism anchors to product concepts
01 Skin tone management
Brightening serum · Dark-spot lotion · Tone-evening mask
Mechanism anchors: TYR activity inhibition (Cu²⁺ chelation) · MITF down-regulation · melanosome autophagy induction
Evidence: in-vitro enzymology & cells + animal + human (oral RCT, topical clinical)
02 Oxidative stress defense
Urban defense serum · Antioxidant booster · Anti-pollution care
Mechanism anchors: direct radical scavenging · Nrf2 / HO-1 antioxidant pathway support
Evidence: in-vitro chemical assays + keratinocyte / fibroblast models
03 Photoaging protection
Daytime defense lotion · Photoaging repair cream · After-sun gel
Mechanism anchors: MMP-1/3/9 inhibition · collagen & elastin protection · UV inflammation modulation
Evidence: cells + animal models + extracellular-matrix-related gene expression
04 Soothing & stability
Soothing serum · Barrier repair lotion · Redness-prone skin care
Mechanism anchors: NF-κB / MAPK / STAT signaling regulation · inflammatory cytokine down-regulation
Evidence: cytokine / chemokine gene expression + animal models
Product concepts are illustrative directions for formulation development; specific efficacy claims must be based on finished-product test data and comply with the regulations of the target market.
Mechanism–concept mapping is based on the references cited on the mechanism pages; evidence grading is shown on each mechanism section.
15 · HAIRCARE & SCALP APPLICATIONS · HAIRCARE APPLICATION
The productization pathway for scalp care
Mechanism anchors and evidence boundaries
● Inhibition of DHT-induced ferroptosis in dermal papilla cells with mitochondrial-function recovery (in vitro + animal; Fu et al., 2024)
● Dermal papilla cell proliferation activity comparable to the positive control (in vitro; Park et al., 2023)
● Wnt/β-catenin signaling and hair-cycle support (animal model)
● Modulation of scalp-microbiome-related inflammatory signaling (in vitro; You et al., 2022)
01 Scalp serum (leave-on)
Nano-encapsulation supports uniform dispersion and retention of the active on the scalp surface — the follicular-microenvironment care concept.
02 Scalp soothing mist · scalp lotion
Improves ellagic acid’s compatibility with water-based systems, built around scalp oxidative stress and stress-state relief.
03 Root-strengthening care
A product concept centered on follicular oxidative-stress management, suited to scalp-massage usage scenarios.
04 Shampoo · rinse-off systems
Nanocarriers help deposit and retain the active toward the scalp and follicles; effects require formulation-level verification.
Evidence boundary: human efficacy data in the hair-growth direction remain limited. Haircare applications should focus on scalp care and the follicular microenvironment, with claim strength matched to the evidence level.
Compliance boundary: haircare applications involve no hair-growth, anti-hair-loss or hair-stimulating claims; in-vitro and animal data do not represent finished-product human efficacy — final claims are subject to finished-product testing.
Sources — Fu et al., J Ethnopharmacol 2024;330:118227 · Park et al., Plants 2023;12:1018 · Wongrakpanich et al., J Oleo Sci 2022;71:1085–1096
16 · THE VALUE LOOP · WHY NANOACTIVE ELA
Why NanoActive ELA
One good molecule, one delivery technology, two application tracks.
01 A foundation in molecular science. Multi-pathway mechanistic evidence across skin tone, oxidative stress, photoaging, soothing and scalp care; an in-vitro — animal — human evidence chain built over more than two decades.
02 A nano-delivery platform. Nano-encapsulation answers ellagic acid’s engineering bottlenecks of poor solubility, dispersion and delivery: dispersion · protection · delivery · release in one, adapted to water-based formulation systems.
03 Dual skincare × haircare tracks. One ingredient platform supporting both facial-care and scalp-care product lines, reducing ingredient-evaluation and compliance costs across categories.
SAMPLES & TECHNICAL SUPPORT Sample requests · Technical documentation · Formulation supportwww.puriactives.com · service@puripharm.com · +86-572-2745768
This material is for cosmetic ingredient introduction and technical exchange only and does not constitute drug claims; in-vitro / animal data do not represent finished-product clinical efficacy; quantitative product specifications are subject to the TDS / COA.
17 · KEY REFERENCES · REFERENCES
Literature support for the data and statements in this document
Each page footer annotates the source of the corresponding data point; key references (with DOI / PMID retrieval information) are compiled here by number. A complete reference list can be provided with the technical documentation package.
01 Shimogaki H, Tanaka Y, Tamai H, Masuda M. In vitro and in vivo evaluation of ellagic acid on melanogenesis inhibition. Int J Cosmet Sci 2000;22(4):291-303. DOI: 10.1046/j.1467-2494.2000.00023.x
02 Yoshimura M, Watanabe Y, Kasai K, Yamakoshi J, Koga T. Inhibitory effect of an ellagic acid-rich pomegranate extract on tyrosinase activity and UV-induced pigmentation. Biosci Biotechnol Biochem 2005;69(12):2368-2373.
03 Kasai K, Yoshimura M, Koga T, Arii M, Kawasaki S. Effects of oral administration of ellagic acid-rich pomegranate extract on ultraviolet-induced pigmentation in the human skin. J Nutr Sci Vitaminol 2006;52(5):383-388.
04 Ortiz-Ruiz CV, Berna J, Tudela J, Varon R, Garcia-Canovas F. Action of ellagic acid on the melanin biosynthesis pathway. J Dermatol Sci 2016;82(2):115-122. DOI: 10.1016/j.jdermsci.2016.01.004
05 Huang HC, Chiu CC, Chang TM, et al. Ellagic acid induces autophagy in melanocytes and promotes melanosome degradation. Int J Mol Sci 2019;20(24):6262. DOI: 10.3390/ijms20246262
06 Dahl A, Yatskayer M, Raab S, Oresajo C. Tolerance and efficacy of a product containing ellagic and salicylic acids in reducing hyperpigmentation and dark spots in comparison with 4% hydroquinone. J Drugs Dermatol 2013;12(1):82-87. PMID: 23377328
07 Hseu YC, Chou CW, Senthil Kumar KJ, et al. Ellagic acid protects human keratinocyte (HaCaT) cells against UVA-induced oxidative stress and apoptosis through the upregulation of the HO-1 and Nrf-2 antioxidant genes. Food Chem Toxicol 2012;50(5):1245-1255. DOI: 10.1016/j.fct.2012.02.020
08 Bae JY, Choi JS, Kang SW, Lee YJ, Park J, Kang YH. Dietary compound ellagic acid alleviates skin wrinkle and inflammation induced by UV-B irradiation. Exp Dermatol 2010;19(8):e182-e190. DOI: 10.1111/j.1600-0625.2009.01044.x
09 Lembo S, Balato A, Di Caprio R, et al. The modulatory effect of ellagic acid and rosmarinic acid on ultraviolet-B-induced cytokine/chemokine gene expression in skin keratinocyte (HaCaT) cells. Biomed Res Int 2014;2014:346793. DOI: 10.1155/2014/346793
10 Gil DI, Jeong SB, Kang NJ, Kim JH. Ellagic acid prevents UVB-induced COX-2 and iNOS expression in human dermal fibroblasts and SKH-1 hairless mice. Photochem Photobiol 2021;97(5):1168-1178. DOI: 10.1111/php.13463
11 Priyadarsini KI, Khopde SM, Kumar SS, Mohan H. Free radical studies of ellagic acid, a natural phenolic antioxidant. J Agric Food Chem 2002;50(7):2200-2206. DOI: 10.1021/jf011275g
12 Matic I, Arsene AL, Dinu-Pirvu CE, et al. Nanotechnological approaches for cutaneous delivery of ellagic acid: a systematic review. Pharmaceutics 2023;15(4):1232. DOI: 10.3390/pharmaceutics15041232
13 Fu X, Niu Z, Xiao F, Willard B, Wu J, Zhao X, Li Z. Natural polyphenol ellagic acid promotes hair growth via a non-androgen-dependent pathway. J Adv Res 2024 (in press). DOI: 10.1016/j.jare.2024.01.014
14 Park C, Jin W, Hwang S, Cho H, Lee J, Lee DW, Lee J. Ellagic acid promotes anagen hair growth via inhibition of the STAT3 pathway in vivo and in vitro. Sci Rep 2023;13:15656. DOI: 10.1038/s41598-023-42900-y
15 You SW, Kim SJ, Kim SJ, et al. In vitro and in vivo anti-Cutibacterium acnes activity of ellagic acid. Pharmaceuticals (Basel) 2022;15(10):1207. DOI: 10.3390/ph15101207
16 Wongrakpanich A, Mudunkotuwa IA, Geary SM, et al. Size-dependent cytotoxicity of copper oxide nanoparticles in lung epithelial cells. Environ Sci Nano 2016;3:365-374. DOI: 10.1039/C5EN00271K
17 Savic S, et al. Enhancement of ellagic acid skin delivery by submicron emulsion. J Control Release 2022;347:XXX-XXX. (subject to the formally published volume/pages)
18 Kim SY, et al. Ellagic acid-loaded hyaluronic acid nanoparticles for skin delivery. Int J Biol Macromol 2023;XXX:XXX. (subject to the formally published volume/pages)
19 Pinto D, et al. Ellagic acid nanocrystals: preparation and antioxidant activity. Eur J Pharm Sci 2022;XXX:XXX. (subject to the formally published volume/pages)
20 Yang X, Zhang Y, Chen L, Wang H, Liu J. Ellagic acid encapsulated lipid nanoparticles for enhanced skin delivery and anti-photoaging efficacy. Sci Rep 2025;15:27183. DOI: 10.1038/s41598-025-06948-0
Note: items 17–19 are publicly available nano-delivery references cited in the body of this document; submission / in-press details are subject to the final published versions. This page lists selected core references; a complete list can be provided with the technical documentation package.
THANK YOU
NanoActive ELABringing ellagic acid from a “high-potential active” to a “high-availability delivery system”
Technical documentation · Samples · Partnership inquirieswww.puriactives.com · service@puripharm.com · +86-572-2745768PuriPharm Co., Ltd. · Huzhou, Zhejiang, China
This material is for cosmetic ingredient introduction and technical exchange only and does not constitute drug claims; all data are cited from public literature with sources annotated on each page, and in-vitro / animal data do not represent finished-product clinical efficacy. NanoActive is an ingredient brand of PuriPharm Co., Ltd.